SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors
SoniVie , a medical device company developing a renal denervation system for hypertension treatment, has appointed Raymond W. Cohen as Chairman of its Board of Directors. Cohen, who is retiring from Axonics following its $3.7 billion sale to Boston Scientific , brings significant experience in the medical technology sector. He previously served as CEO of Axonics, which he co-founded in 2013 and led to become the top-ranked company in the 2021 Deloitte Technology Fast 500™. Cohen also has relevant expertise in renal denervation from his time as CEO of Vessix Vascular, which was acquired by Boston Scientific in 2012.
SoniVie, un'azienda di dispositivi medici che sviluppa un sistema di denervazione renale per il trattamento dell'ipertensione, ha nominato Raymond W. Cohen come Presidente del suo Consiglio di Amministrazione. Cohen, che si ritira da Axonics dopo la vendita di 3,7 miliardi di dollari a Boston Scientific, porta con sé un'esperienza significativa nel settore della tecnologia medica. In precedenza ha ricoperto il ruolo di CEO di Axonics, che ha cofondato nel 2013 e ha guidato per diventare l'azienda di punta nella classifica Deloitte Technology Fast 500™ del 2021. Cohen ha anche una rilevante esperienza nella denervazione renale grazie al suo tempo come CEO di Vessix Vascular, acquisita da Boston Scientific nel 2012.
SoniVie, una empresa de dispositivos médicos que desarrolla un sistema de denervación renal para el tratamiento de la hipertensión, ha nombrado a Raymond W. Cohen como Presidente de su Junta Directiva. Cohen, quien se retira de Axonics tras la venta de 3.7 mil millones de dólares a Boston Scientific, aporta una experiencia significativa en el sector de la tecnología médica. Anteriormente, ocupó el cargo de CEO de Axonics, que cofundó en 2013 y que lideró para convertirse en la empresa mejor clasificada en el Deloitte Technology Fast 500™ de 2021. Cohen también posee una experiencia relevante en denervación renal de su tiempo como CEO de Vessix Vascular, que fue adquirida por Boston Scientific en 2012.
SoniVie는 고혈압 치료를 위한 신장 신경 차단 시스템을 개발하는 의료기기 회사로, Raymond W. Cohen을 이사회의 의장으로 임명했습니다. Cohen은 Boston Scientific에 3.7억 달러에 매각된 Axonics에서 은퇴하며, 의료 기술 분야에서 상당한 경험을 가지고 있습니다. 그는 2013년에 공동 창립한 Axonics의 CEO로 활동하며, 2021년 Deloitte Technology Fast 500™에서 가장 높은 순위를 기록한 회사로 이끌었습니다. Cohen은 2012년 Boston Scientific에 인수된 Vessix Vascular의 CEO로서 신장 신경 차단에 대한 관련 전문성도 가지고 있습니다.
SoniVie, une entreprise de dispositifs médicaux développant un système de dénervation rénale pour le traitement de l'hypertension, a nommé Raymond W. Cohen en tant que Président de son Conseil d'Administration. Cohen, qui prend sa retraite de Axonics après sa vente de 3,7 milliards de dollars à Boston Scientific, apporte une expérience significative dans le secteur de la technologie médicale. Il a précédemment été PDG d'Axonics, qu'il a cofondée en 2013 et qu'il a dirigée pour devenir l'entreprise la mieux classée dans le Deloitte Technology Fast 500™ de 2021. Cohen possède également une expertise pertinente en dénervation rénale acquise lors de son mandat en tant que PDG de Vessix Vascular, qui a été acquise par Boston Scientific en 2012.
SoniVie, ein Unternehmen für medizinische Geräte, das ein System zur Nervenabtrennung der Nieren zur Behandlung von Bluthochdruck entwickelt, hat Raymond W. Cohen zum Vorsitzenden seines Vorstands ernannt. Cohen, der nach dem Verkauf von Axonics für 3,7 Milliarden Dollar an Boston Scientific in den Ruhestand geht, bringt beträchtliche Erfahrung im Bereich der Medizintechnologie mit. Zuvor war er CEO von Axonics, das er 2013 mitbegründet hat und das er zur führenden Firma im Deloitte Technology Fast 500™ des Jahres 2021 entwickelte. Cohen hat auch relevante Expertise in der Nervenabtrennung der Nieren aus seiner Zeit als CEO von Vessix Vascular, das 2012 von Boston Scientific übernommen wurde.
- Appointment of experienced medtech executive with specific renal denervation expertise
- New chairman has successful track record of leading companies to significant exits ($3.7B Axonics sale)
- Chairman's experience aligns with company's FDA approval pursuit and commercialization plans
- None.
Mr. Cohen has served as the chief executive officer and member of the board of directors of Axonics, Inc., an
Cohen is retiring from Axonics following the close of its
Prior to Axonics, Cohen was the CEO of Vessix Vascular, Inc. (privately held) which developed a catheter based renal denervation system that was acquired by BSX in late 2012.
Tomaso Zambelli, CEO of SoniVie, said "We look forward to benefiting from Mr. Cohen's broad experience in growing Medtech companies and moreover his expertise in renal denervation as we execute our PMA study for US FDA approval and make plans to commercialize our product."
About Raymond W. Cohen
An accredited public company director with over 40 years of experience in the life sciences industry, Cohen also serves as an independent director of Kestra Medical Technologies, Inc., (privately held) a commercial stage company manufacturing and marketing a wearable defibrillator product for patients at temporary risk of cardiac arrest.
Cohen recently received the 2024 MedTech MVP Award and was also named Businessperson of the Year by the Orange County Business Journal. In 2021, Mr. Cohen received a lifetime achievement award from SoCal Bio for his four decades of work in medical technology. In late 2020, Mr. Cohen was named as Entrepreneur of the Year by Ernst & Young for the Pacific Southwest United States.
About SoniVie Ltd.
SoniVie has developed TIVUS™ (Therapeutic Intra-Vascular Ultrasound System) which employs high-frequency non-focused ultrasound energy to ablate nerves in the renal artery to decrease blood pressure for patients suffering from hypertension, a condition impacting millions of people worldwide and substantially increasing their risk of heart attack, stroke and kidney failure. In July 2024, the United States FDA approved the company's PMA study which is now enrolling patients in the US,
For more information, please go to www.sonivie.com
PR Contact:
Tomaso Zambelli, CEO
Sonivie Ltd.
tomaso@sonivie.com
View original content:https://www.prnewswire.com/news-releases/sonivie-ltd-appoints-veteran-medtech-executive-raymond-w-cohen-as-chairman-of-its-board-of-directors-302305823.html
SOURCE SoniVie
FAQ
Who is the new Chairman of SoniVie's Board of Directors?
What is SoniVie's main product focus?
Why did Raymond Cohen leave his position at Axonics?
What is Raymond Cohen's relevant experience in renal denervation?
